Adma Biologics (ADMA) Non Operating Income (2011 - 2025)

Adma Biologics' Non Operating Income history runs 13 years deep, the most recent figure standing at -$1.2 million for Q4 2025.

• Quarterly Non Operating Income rose 67.98% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$8.8 million (up 33.79% YoY) and the FY2025 annual result came in at -$8.8 million, up 33.78% from the prior year.
• Non Operating Income was -$1.2 million for Q4 2025 at Adma Biologics, up from -$3.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at -$1.2 million in Q4 2025 and bottomed at -$31.9 million in Q4 2023.
• A 5-year average of -$5.3 million and a median of -$3.5 million in 2021 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income slumped 416.39% — and 2024, when it surged 88.68%.
• Adma Biologics' Non Operating Income stood at -$3.5 million in 2021, then slumped by 78.5% to -$6.2 million in 2022, then slumped by 416.39% to -$31.9 million in 2023, then jumped by 88.68% to -$3.6 million in 2024, then surged by 67.98% to -$1.2 million in 2025.
• Business Quant data shows ADMA's Non Operating Income at -$1.2 million in Q4 2025, -$3.5 million in Q3 2025, and -$2.7 million in Q2 2025.